Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Vaxart Inc (VXRT)

Vaxart Inc (VXRT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 168,755
  • Shares Outstanding, K 240,495
  • Annual Sales, $ 28,700 K
  • Annual Income, $ -66,950 K
  • EBIT $ -49 M
  • EBITDA $ -41 M
  • 60-Month Beta 0.95
  • Price/Sales 1.46
  • Price/Cash Flow N/A
  • Price/Book 5.56
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.23
  • Most Recent Earnings $-0.04 on 11/13/25
  • Next Earnings Date 03/19/26
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Drugs

Options Overview Details

View History
  • Implied Volatility 0.00% (unch)
  • Historical Volatility 177.46%
  • IV Percentile 0%
  • IV Rank N/A
  • IV High 0.00% on N/A
  • IV Low 0.00% on N/A
  • Expected Move (DTE 0) 0.3655 (56.23%)
  • Put/Call Vol Ratio N/A
  • Today's Volume N/A
  • Volume Avg (30-Day) N/A
  • Put/Call OI Ratio N/A
  • Today's Open Interest N/A
  • Open Int (30-Day) N/A
  • Expected Range 0.2845 to 1.0155

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.05
  • Growth Rate Est. (year over year) +1,998,100.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.3401 +106.32%
on 12/19/25
0.8449 -16.95%
on 01/12/26
+0.3317 (+89.65%)
since 12/16/25
3-Month
0.3050 +130.07%
on 11/04/25
0.8449 -16.95%
on 01/12/26
+0.3467 (+97.66%)
since 10/16/25
52-Week
0.2606 +169.26%
on 07/09/25
0.8449 -16.95%
on 01/12/26
-0.0398 (-5.37%)
since 01/16/25

Most Recent Stories

More News
Vaxart Publishes Positive Data for its Oral Bivalent Norovirus Candidate in Lactating Women and Their Infants

Vaccine was safe and well-tolerated and led to a significant increase in norovirus-specific antibodies in serum and breast milk Norovirus-specific IgA in infant stool correlated with breast milk IgA,...

VXRT : 0.7017 (+7.95%)
Vaxart to Participate in the Global BioInnovation Forum on January 13, 2026

SOUTH SAN FRANCISCO, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) (“Vaxart or “the Company”), a clinical-stage biotechnology company developing a range of oral recombinant pill...

VXRT : 0.7017 (+7.95%)
Vaxart Provides Business Update and Reports Third Quarter 2025 Financial Results

Entered into an exclusive license agreement with Dynavax for the Company’s COVID-19 oral pill vaccine candidate for potential cumulative proceeds of up to $700 million plus royalties Completed enrollment...

VXRT : 0.7017 (+7.95%)
Vaxart to Host Upcoming Conference Calls

Third quarter 2025 results conference call to be held on November 13 at 4:30 p.m. ET Stockholder fireside chat to be held on November 18 at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., Nov. 07,...

VXRT : 0.7017 (+7.95%)
Dynavax Reports Third Quarter 2025 Financial Results and Announces New $100 Million Share Repurchase Program

EMERYVILLE, Calif. , Nov. 5, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines,...

DVAX : 15.63 (+0.06%)
VXRT : 0.7017 (+7.95%)
Dynavax Enters Exclusive License Agreement for Vaxart's Novel Oral COVID-19 Vaccine Program

EMERYVILLE, Calif. and SOUTH SAN FRANCISCO, Calif. , Nov. 5, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing...

DVAX : 15.63 (+0.06%)
VXRT : 0.7017 (+7.95%)
Vaxart to Present Research on Second-Generation Norovirus Oral Pill Vaccine Candidate at IDWeek 2025

SOUTH SAN FRANCISCO, Calif., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) (“Vaxart”), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based...

VXRT : 0.7017 (+7.95%)
Vaxart Secures Funding for COVID-19 Trial

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Vaxart (...

VXRT : 0.7017 (+7.95%)
Vaxart to Showcase its Norovirus and COVID-19 Oral Pill Vaccine Candidates at World Vaccine Congress Europe 2025

SOUTH SAN FRANCISCO, Calif., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing a range of oral recombinant...

VXRT : 0.7017 (+7.95%)
Vaxart Appoints W. Mark Watson as Lead Independent Director

In process of adopting a Director stock ownership policy to reinforce commitment of aligning the Board’s interests with stockholders Vaxart encourages all stockholders of record on July 29,...

VXRT : 0.7017 (+7.95%)

Business Summary

Vaxart, Inc. is a clinical-stage company developing a range of oral recombinant vaccines based on its proprietary delivery platform. The company's vaccines are administered using convenient room temperature-stable tablets that can be stored and shipped without refrigeration and eliminate risk of needle-stick...

See More

Key Turning Points

3rd Resistance Point 0.8811
2nd Resistance Point 0.8206
1st Resistance Point 0.7611
Last Price 0.7017
1st Support Level 0.6411
2nd Support Level 0.5806
3rd Support Level 0.5211

See More

52-Week High 0.8449
Last Price 0.7017
Fibonacci 61.8% 0.6217
Fibonacci 50% 0.5527
Fibonacci 38.2% 0.4838
52-Week Low 0.2606

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar